April 6, 2020
BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough
– Topline data on track for mid-year 2020 – LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company”…